| 产品描述: | Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 . Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. |
| 体内研究: |
Cantuzumab ravtansine(huC242-DM4;静脉注射;3.4 mg/kg;单剂量)可使携带 N87 人胃肿瘤异种移植物的 SCID 小鼠的肿瘤完全消退,在低于 2 mg/kg 的剂量下观察到显着的肿瘤消退 。 Cantuzumab ravtansine (huC242-DM4) 在携带人结肠肿瘤异种移植物 HT29 和 COLO 205 细胞的小鼠中也有疗效,且无毒副作用。 |
| 参考文献: |
1. Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement): 334-335. 2. Olga Ab, et al. Activity of huC242 웿 Ů ñ 샮㡽䇘睜⪰ޏࠃ 䇩睜 䇩睜Ȃ Ӥ 晐睦Ӥ 晐睦Ӥ 峀睜 弴睜 ڤ 犐ƈ |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0 ml |
0 ml |
0 ml |
| 5 mM |
0 ml |
0 ml |
0 ml |
| 10 mM |
0 ml |
0 ml |
0 ml |
| 50 mM |
0 ml |
0 ml |
0 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |